- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-Q Quarterly report
- 10.1 Amended and Restated License Agreement
- 10.2 Exclusive Patent License Agreement
- 10.3 Non-exclusive Sub-license Agreement
- 10.4 Lease, Between Abbey Biopharma Corp.
- 10.5 Rental Agreement, Between Abbey Biopharma Corp.
- 10.6 Warrant to Purchase Stock of Avigenics, Inc.
- 10.7 Warrant to Purchase Stock of Avigenics, Inc.
- 10.8 Form of Indemnification Agreement Between Synageva Biopharma Corp.
- 10.9 Form of Indemnification Agreement Between Synageva Biopharma Corp.
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO Certification
- 32.2 Section 906 CFO Certification
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Synageva BioPharma Corp. (the “Company”) for the quarterly period ended September 30, 2011 as filed with Securities and Exchange Commission on the date hereof (the “Report”), I, Carsten Boess, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Carsten Boess |
Carsten Boess Chief Financial Officer |
November 14, 2011
The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.
A signed original of this written statement required by § 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.